He sighed, and I pictured him shaking his head.
‘Well, you were right about the list,’ he said eventually. ‘It was incredible.’
‘Why’s that?’
‘Those out-of-state numbers? You were right. They all seem to be cult members living under assumed names. Most are sick, but I got to speak to some of them.’ There was a brief pause, during which I heard him sighing again. ‘Of the three I was originally looking for, two are in the hospital and one is at home suffering from severe migraines.’
I could tell by his tone that despite having been reassigned he was excited at the progress he’d made.
‘It took a while to get anyone to speak to me, but when I did, it was amazing. The longest conversation I had was with a girl called Beth Lipski. It seems the standard Dekedelia make-over involves a completely new identity – chemically-assisted alteration of metabolism, plastic surgery, new “designated” relatives, the lot. And just like you said, career advancement is the measure of a successful new identity, with 60 per cent of income going back into the organization. Shit, it’s like a cross between the Freemasons and the Witness Protection Program.’
‘Why did she talk?’
‘Because she’s afraid. Tauber has cut off all contact with her, and she feels nervous and lost. She has a permanent headache and can’t work properly. She doesn’t know what’s happening to her. I don’t even think she knows she’s been taking a drug – and I didn’t want to push her over the edge by bringing it up. She was paranoid about talking to me in the first place, but then once she started she couldn’t stop.’
‘So how do you think he gives them the drug?’
‘Apparently, he has them all on a programme of vitamins and special diet supplements, so I guess he slips it in there somehow. And that’s obviously the source of his power over these people, and of his supposed charisma.’ He paused. I heard him stamping his foot, or banging his fist on something. Then he said, ‘Damn! I really can’t believe this shit. I’ve never worked on such an interesting case before.’
I didn’t have time for this now – Kenny Sanchez having a career crisis down the phone at me. I felt a slight queasiness all of a sudden. I took a deep breath, and then asked him if he had come up with anything on United Labtech.
He sighed again.
‘Yeah, I did,’ he said, ‘one thing anyway. It’s owned by the pharmaceutical company, Eiben-Chemcorp.’
Soon after that, I told him I had to go, that I was at work. I thanked him, wished him luck, and got off the phone as quickly as I could.
I put the phone down on the table and stood up.
I walked across the room, slowly, and stood at the windows. It was a clear, sunny day in Manhattan and from up here on the sixty-second floor everything was visible, there to be seen, and picked out, every landmark, every architectural feature – including some less obvious ones, such as the Celestial Building over to my right, or the old Port Authority Terminal further down, on Eighth Avenue, where Kerr & Dexter had their offices. Standing at this window, in fact, I saw that my whole life was laid out in front of me, like a sequence of tiny incisions in the vast microchip of the city – street corners, apartments, delis, liquor stores, movie-theaters. But now, instead of a deeper and more permanent line being cut into the surface, these minute nicks were in danger of being smoothed over and levelled off.
I turned around and stared at the plain white walls on the other side of the room, and at the grey carpet and at the anonymous company furniture. I hadn’t given in to panic yet – though it surely wouldn’t be long in coming. The press conference was scheduled for the afternoon, and already the thought of it filled me with a sense of dread.
But then something else occurred to me, and with the single-mindedness of a condemned man, I latched on to it – and wouldn’t let go.
Sanchez had mentioned Eiben-Chemcorp. I knew I’d heard that name somewhere quite recently, and after a couple of minutes I remembered where. I’d seen it at Vernon’s that day – in the Boston Globe. Vernon had apparently been reading about an upcoming product liability trial in Massachusetts. As far as I could recall, a teenage girl who’d been taking Triburbazine had murdered her best friend and then killed herself.
I walked back over to the table and sat in front of the laptop. I went online and searched the Globe archives for more detail on the story.
The girl’s family had filed a lawsuit looking for punitive damages against Eiben-Chemcorp. In the trial, the company would be defending charges that its anti-depressant drug had caused ‘loss of impulse control’ and ‘suicidal ideation’ in the girl. Dave Morgenthaler, a personal injury lawyer, was to be the lead counsel representing the plaintiffs, and according to one article I read, he had spent the last six months collecting depositions from expert witnesses – among them scientists who’d been involved in the development and production of Triburbazine, and psychiatrists who would be willing to testify that Triburbazine was potentially harmful.
My mind was racing now. I picked up a pen and started doodling on a piece of paper, trying to link all of this together.
Eiben-Chemcorp owned Labtech, which was where MDT seemed to have come from. That meant, in effect, that MDT had been developed and produced by an international pharmaceutical corporation. This corporation, in turn, was facing high profile – and potentially very damaging – litigation.
In fact – I turned back to the computer and went into one of the financial websites, and there it was – due to adverse publicity surrounding the case, Eiben-Chemcorp’s stock had already suffered quite a lot, having apparently dropped to 69⅞ from a high earlier in the year of 87¼. This growing public interest in the case would probably continue as the trial date approached. I found numerous articles that had already touched on what would surely be a key point in the triaclass="underline" if human behaviour was all about synapses and serotonin, then where did free will fit into the picture? Where did personal responsibility end and brain chemistry begin?
Eiben-Chemcorp, in short, was in a very vulnerable position.
I was too, of course – but what I then wondered was how I could use my knowledge of MDT to leverage some advantage out of Eiben-Chemcorp. A supply of MDT in return for not talking to Dave Morgenthaler, perhaps?
I stood up and wandered around the room.
It seemed to me that information coming out in court about an Eiben-Chemcorp product that hadn’t ever been tested, and had already caused numerous deaths, would have a devastating effect on the company’s share price. It was a stark, high-risk option, but given the circumstances it was probably the only option I had left.
I passed by the window again, but didn’t look out this time. After a good deal of thought, I decided that the most practical first step would be to establish contact with Dave Morgenthaler. I would have to be careful how I approached him, but to pose a credible threat to Eiben-Chemcorp, I would need to have Morgenthaler primed for the kill. I would need to be able to set him loose at a moment’s notice.
I made some enquiries and found the number for his office in Boston. I called it immediately and asked to speak to him, but he was out of the office for the day. I left my cellphone number and a message: that I had some ‘explosive’ information about Eiben-Chemcorp and wanted to meet him as soon as possible to discuss it.
When I put the phone down again, I tried to get back to work, to redirect my attention to the MCL-Abraxas deal and to the press conference in the afternoon, but I found it very difficult. I kept reliving the past few weeks in my mind and wishing I’d done this or that – wishing, for instance, that I’d investigated Deke Tauber a little earlier, which might have meant reaching Todd Ellis before he left United Labtech…